Genetics in KS Sample Clauses

Genetics in KS. 4.1.3.1 MIXED LINEAGE LEUKEMIA 2 GENE (MLL2) The first association of KS with a genetic mutation was made in 2010 when, following WES of 10 unrelated patients, nonsense or frameshift mutations in the MLL2 gene, on chromosome 12q12-14, were identified in seven (Xx et al. 2010). MLL2 is the paralog of MLL1 (associated with chromosomal rearrangements in acute myeloid, myeloblastic and lymphatic leukaemia); a product of a gene duplication process. The name MLL (mixed lineage leukaemia) originates from its association to the pathogenesis of leukaemia (Ziemin-van der Poel et al. 1991, Xxxxxxx et al. 1992). MLL2 consists of 54 coding exons and encodes the histone H3 lysine 4 specific methyltransferase. Subsequent Sanger sequencing detected mutations in MLL2 in 2 of the 3 remaining individuals out of the initial 10 patients with KS and in 26 of 43 additional cases (Xx et al. 2010). In twelve KS patients, where parental DNA was available and tested, mutations in MLL2 were detected in only two families. Overall, 33 MLL2 mutations were identified in 35 of 53 families (66%) with KS (Xx et al. 2010). To date, 247 mutations in MLL2 have been described in KS patients (Table 18). All mutations described are heterozygous with the majority being truncating. They thus appear to behave in a dominant fashion. Overall, the most common mutation types identified were nonsense (164) and frameshift (88). Of interest is that the majority of mutations described are de novo with only four families identified to have proven mutations in more than one family member. This could reflect the lack of ancestral DNA availability to facilitate further testing within families or a possible reduced fertility status (Xxxxxxxx et al. 2011, Xx et al. 2011, Xxxxxx et al. 2011, Xxxxxxxxx et al. 2011, Xxxxx et al. 2012, Xxxxxxx-Xxxxxx et al. 2012, Xxxxxxxxxxxx and Xxxxxxx 2013, Xxxxxxxxxxxxx et al. 2013, Xxxxxx et al. 2013, Xxxxxxx et al. 2014). Author Total No patients/ No of mutations/de novo Nonsense Frameshift Missense Splice site/Indel Xxxxxxxxx et al 2011 45/34/27 11 17 2 4 Xx et al 2011 34/18/11 3 6 7 2 Xxxxxx et al 2011 65/42/38 17 13 7 3/3 Xxxxxxxx et al 2011 110/81/25 37 22 16 3/3 Banka et al 2012 116/74/7 25 30 9 10 Kokitsu-Nakata et al 2012 2/1/none - - 1 - Xxxxxx et al 2012 2/2/none 1 - 1 - Xxxxxxxxxxxxx et al 2013 86/45/34 31 - 10 4 Xxxxxx et al 2013 81/50/35 35 Xxxxxxx et al 2014 18/10/none 4 4 2 - Table 18: Number of mutations in MLL2 reported in the literature. Mutations are categoris...
Sample 1
AutoNDA by SimpleDocs

Related to Genetics in KS

  • ETHICS IN PUBLIC CONTRACTING This Contract incorporates by reference Article 9 of the Arlington County Purchasing Resolution, as well as all state and federal laws related to ethics, conflicts of interest or bribery, including the State and Local Government Conflict of Interests Act (Code of Virginia § 2.2-3100 et seq.), the Virginia Governmental Frauds Act (Code of Virginia § 18.2-498.1 et seq.) and Articles 2 and 3 of Chapter 10 of Title 18.2 of the Code of Virginia, as amended (§ 18.2-438 et seq.). The Contractor certifies that its proposal was made without collusion or fraud; that it has not offered or received any kickbacks or inducements from any other offeror, supplier, manufacturer or subcontractor; and that it has not conferred on any public employee having official responsibility for this procurement any payment, loan, subscription, advance, deposit of money, services or anything of more than nominal value, present or promised, unless consideration of substantially equal or greater value was exchanged.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Joint Network Implementation and Grooming Process Upon request of either Party, the Parties shall jointly develop an implementation and grooming process (the “Joint Grooming Process” or “Joint Process”) which may define and detail, inter alia:

  • Research, Science and Technology Cooperation 1. The aims of cooperation in research, science and technology, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to build on existing agreements already in place for cooperation on research, science and technology; (b) to encourage, where appropriate, government agencies, research institutions, universities, private companies and other research organizations in the Parties to conclude direct arrangements in support of cooperative activities, programs or projects within the framework of this Agreement, specially related to trade and commerce; and (c) to focus cooperative activities towards sectors where mutual and complementary interests exist, with special emphasis on information and communication technologies and software development to facilitate trade between the Parties. 2. The Parties will encourage and facilitate, as appropriate, the following activities including, but not limited to:

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • First Source Hiring Program Contractor must comply with all of the provisions of the First Source Hiring Program, Chapter 83 of the San Francisco Administrative Code, that apply to this Agreement, and Contractor is subject to the enforcement and penalty provisions in Chapter 83.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!